Cannabis and Neuropathic Pain
What the evidence actually says about using cannabis to treat nerve pain, by condition and confidence level.
Neuropathic pain is one of the few areas where cannabis has decent — not great — clinical evidence. Multiple controlled trials show modest pain reduction for some patients, particularly with HIV neuropathy, MS-related pain, and mixed chronic neuropathic conditions. Effect sizes are similar to gabapentinoids, with different side effects. It is not a miracle cure, the number needed to treat is high, and roughly one in three patients quits due to side effects or non-response. Anyone selling certainty here — pro or con — is overselling.
Not Medical Advice
This article is not medical advice. It summarizes published research for educational purposes. Neuropathic pain has many causes and interacts with other conditions and medications. If you have nerve pain, talk to a clinician — ideally one familiar with both pain medicine and cannabinoids. Do not stop prescribed medications based on this article. Cannabis interacts with several drugs (warfarin, some antiepileptics, CNS depressants) and is contraindicated in some psychiatric conditions.
Plain-Language Summary
Neuropathic pain is pain caused by damage or disease affecting the nerves themselves — think shooting, burning, electric, or pins-and-needles pain rather than a dull ache. It includes diabetic neuropathy, post-shingles pain, MS-related pain, sciatica, HIV neuropathy, and chemotherapy-induced neuropathy. Standard treatments (gabapentin, pregabalin, duloxetine, amitriptyline, opioids) help some people but fail or cause intolerable side effects in many.
Cannabis has been studied for neuropathic pain in dozens of randomized trials. The honest summary: it works modestly, for some people, with a side-effect profile most patients can tolerate but a meaningful minority cannot. It is roughly comparable in effect size to first-line drugs like gabapentin Strong evidence [1][2]. It is not dramatically better, and the trials are mostly short (weeks to a few months).
What Probably Works
Nabiximols (Sativex) for MS-related neuropathic pain and spasticity-associated pain. This is the strongest evidence base. Multiple RCTs and meta-analyses show modest but reproducible pain reduction versus placebo Strong evidence [1][3][4]. Approved for this indication in the UK, Canada, Germany, Spain, and others.
Smoked or vaporized cannabis for HIV-associated sensory neuropathy. Two well-designed RCTs by Abrams and Ellis (UCSF/UCSD) showed roughly 30% pain reduction in responders, with a number needed to treat around 3-5 Strong evidence [5][6].
Mixed chronic neuropathic pain in adults. The 2017 National Academies of Sciences report concluded there is conclusive or substantial evidence that cannabis is effective for chronic pain in adults, with neuropathic pain the best-represented subtype in the underlying trials Strong evidence [2]. Effect sizes are modest — typically a 20-30% reduction in pain scores versus 15-20% on placebo.
What Might Work
Diabetic peripheral neuropathy. Small RCTs of inhaled cannabis (Wallace 2015) showed dose-dependent pain reduction, but trials are few and short Weak / limited [7]. Reasonable to try when standard agents fail.
Spinal cord injury neuropathic pain. Limited trials suggest benefit from oral THC and nabiximols, but sample sizes are small Weak / limited [8].
CBD alone for neuropathic pain. Biologically plausible and popular, but high-quality RCTs of isolated CBD for neuropathic pain in humans are sparse and largely negative or underpowered Weak / limited. Most positive trials use THC-containing products. See CBD.
What Doesn't Work or Has Weak Evidence
Chemotherapy-induced peripheral neuropathy (CIPN). Despite enthusiasm, controlled trials of nabiximols and oral cannabinoids for CIPN have been mostly negative or inconclusive Weak / limited [9]. This is surprising and disappointing given the unmet need.
Topical CBD or cannabis creams for nerve pain. Heavily marketed, minimally studied. One small RCT showed benefit for peripheral neuropathy symptoms [10], but evidence overall is thin Weak / limited. Transdermal absorption of cannabinoids is poor.
"Indica is better for pain than sativa." This is folklore, not pharmacology. The indica/sativa distinction does not reliably predict chemical composition or clinical effect No data. See Indica vs Sativa.
Specific terpene profiles (e.g., myrcene, caryophyllene) for neuropathic pain. Preclinical signal exists for beta-caryophyllene as a CB2 agonist, but no robust human trials Weak / limited.
What We Don't Know
- Long-term efficacy. Most trials run 2-15 weeks. Whether benefit persists over years, or whether tolerance erodes it, is unclear No data.
- Optimal THC:CBD ratio. Nabiximols uses 1:1, but whether this is optimal versus THC-dominant or other ratios for nerve pain has not been rigorously compared.
- Best route of administration. Inhaled acts fast but is short-lived; oral lasts longer but is harder to titrate. No head-to-head trials for neuropathic pain specifically.
- Who responds. No reliable biomarker or clinical predictor identifies likely responders before a trial.
- Opioid-sparing effect. Observational data suggest cannabis users reduce opioid doses; RCT evidence is mixed and weaker than the headlines suggest Disputed [11].
Comparison With Standard Treatments
First-line treatments for neuropathic pain per international guidelines (NeuPSIG, NICE) are gabapentin/pregabalin, SNRIs (duloxetine, venlafaxine), and tricyclics (amitriptyline, nortriptyline) [12][13].
| Treatment | NNT (approx) | Common issues | |---|---|---| | Tricyclics | 3-4 | Anticholinergic, cardiac, sedation | | SNRIs | 6-7 | Nausea, BP, withdrawal | | Gabapentinoids | 7-8 | Sedation, weight gain, misuse | | Opioids (tramadol/strong) | 4-5 | Dependence, constipation, overdose risk | | Cannabinoids | 5-11 | Cognitive effects, dizziness, psychiatric risk |
Cannabinoids sit in roughly the same effect-size range as gabapentinoids, with a different side-effect trade-off. Guidelines generally place them as third-line or adjunctive, not because they are clearly worse, but because the evidence base is smaller and longer-term safety less established Strong evidence [12].
Risks and Side Effects
Common, dose-related, usually mild-to-moderate: dizziness, dry mouth, fatigue, cognitive slowing, euphoria or dysphoria, and impaired coordination. Roughly 1 in 3 patients in trials discontinues due to side effects Strong evidence [1][2].
More serious concerns:
- Psychiatric risk. THC can precipitate or worsen psychosis in predisposed individuals. Avoid in personal or strong family history of schizophrenia or bipolar disorder.
- Cannabis use disorder. Roughly 9-10% of adult users develop problematic use; higher with daily use Strong evidence [14].
- Driving impairment. Significant for hours after inhaled use, longer after oral.
- Drug interactions. CBD inhibits CYP2C9, CYP2C19, CYP3A4 — relevant for warfarin, clobazam, some statins, tacrolimus.
- Cardiovascular. Caution in unstable angina, recent MI, arrhythmias.
- Pregnancy/breastfeeding. Avoid.
For a practical primer on dosing approach, see Microdosing Cannabis and THC.
Sources
- Peer-reviewed Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018;3:CD012182.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. ↗
- Peer-reviewed Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- Peer-reviewed Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1-3):210-220.
- Peer-reviewed Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515-521.
- Peer-reviewed Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672-680.
- Peer-reviewed Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. Journal of Pain. 2015;16(7):616-627.
- Peer-reviewed Wilsey B, Marcotte TD, Deutsch R, et al. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. Journal of Pain. 2016;17(9):982-1000.
- Peer-reviewed Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management. 2014;47(1):166-173.
- Peer-reviewed Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Current Pharmaceutical Biotechnology. 2020;21(5):390-402.
- Peer-reviewed Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health. 2018;3(7):e341-e350.
- Peer-reviewed Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology. 2015;14(2):162-173.
- Government National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in non-specialist settings. Clinical guideline CG173. 2013, updated 2020. ↗
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...